General Information of This Peptide
Peptide ID
PEP01017
Peptide Name
R-C12
Sequence
CH3-(CH2)10-CO-NHRGWFWFRAMRSIAFIARERLREHL-CONH2
Peptide Type
Linear
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
R-C12-4 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Tumor growth inhibition value (TGI)
38.00%
Administration Time 6 days
Administration Dosage 200 μL 15 mg/kg
MOA of PDC
In this study, we would investigate the co-modification of fatty acids and monosaccharides in anticancer peptides, as we expect to optimize the selectivity and cytotoxicity of the peptide at the same time. Based on our previous study, the lipopeptide R-C12 was selected as a template to perform glucose derivative modification at different positions as we supposed that the glucose derivative modification position in R-C12 might be a crucial factor in its selectivity and activity optimization. The glucose derivative was covalently coupled to different sites in R-C12 through its -amino group of a Lys residue, which was obtained by replacing the Arg residue. R-C12 contains seven Arg residues, accordingly, seven glycolipid peptides were designed and synthesized, which were named R-C12-1, R-C12-2, R-C12-3, R-C12-4, R-C12-5, R-C12-6, and R-C12-7. Various physiochemical properties including the hydrodynamic size, ζ-potential, secondary structure, and hydrophobicity were determined to explain the different cytotoxicity and selectivity of these glycolipid peptides. On the other hand, the strength of the binding between glycolipid peptides and the cancer cells mediated by GLUT1 has also been explored. The most optimized glycolipid peptide R-C12-4 demonstrated significant cytotoxicity and antimetastasis in vitro and in vivo, which indicated that it may be a good lead for anticancer drug development.

   Click to Show/Hide
Description
For the subcutaneous transplantation model, R-C12 or R-C12-4 was injected intraperitoneally every other day at the dose of 15 mg/kg. As shown in Figure 7A,B, after 12 days, R-C12-4 and R-C12 have a significant inhibition effect on the BALB/c mice tumor volume compared to the control group (p < 0.01 and p < 0.05, respectively). For the metastasis model, R-C12 or R-C12-4 was applied by the tail intravenous injection every 2 days at the dose of 10 mg/kg. As shown in Figure 7D, significantly fewer metastatic nodules from the lungs of Kunming (KM) mice were observed in the R-C12-4 and R-C12 treatment groups compared to the control and this result was confirmed by the H&E staining of lung sections. Visible tumor nodules were counted on the surface of the lung demonstrating a significant difference between the control and R-C12 and R-C12-4 treatment groups (p < 0.05). It is noteworthy that both R-C12 and R-C12-4 did not affect the mouse body weight either in the subcutaneous transplantation model or in the metastasis model, indicating that these peptides did not diminish their overall health.

   Click to Show/Hide
In Vivo Model BALB/c mice B16-F10 cells xenograft model.
In Vitro Model Mouse melanoma B16-F10 cell CVCL_0159
Experiment 2 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Tumor growth inhibition value (TGI)
50.00%
Administration Time 3 days
Administration Dosage 200 μL 15 mg/kg
MOA of PDC
In this study, we would investigate the co-modification of fatty acids and monosaccharides in anticancer peptides, as we expect to optimize the selectivity and cytotoxicity of the peptide at the same time. Based on our previous study, the lipopeptide R-C12 was selected as a template to perform glucose derivative modification at different positions as we supposed that the glucose derivative modification position in R-C12 might be a crucial factor in its selectivity and activity optimization. The glucose derivative was covalently coupled to different sites in R-C12 through its -amino group of a Lys residue, which was obtained by replacing the Arg residue. R-C12 contains seven Arg residues, accordingly, seven glycolipid peptides were designed and synthesized, which were named R-C12-1, R-C12-2, R-C12-3, R-C12-4, R-C12-5, R-C12-6, and R-C12-7. Various physiochemical properties including the hydrodynamic size, ζ-potential, secondary structure, and hydrophobicity were determined to explain the different cytotoxicity and selectivity of these glycolipid peptides. On the other hand, the strength of the binding between glycolipid peptides and the cancer cells mediated by GLUT1 has also been explored. The most optimized glycolipid peptide R-C12-4 demonstrated significant cytotoxicity and antimetastasis in vitro and in vivo, which indicated that it may be a good lead for anticancer drug development.

   Click to Show/Hide
Description
For the subcutaneous transplantation model, R-C12 or R-C12-4 was injected intraperitoneally every other day at the dose of 15 mg/kg. As shown in Figure 7A,B, after 12 days, R-C12-4 and R-C12 have a significant inhibition effect on the BALB/c mice tumor volume compared to the control group (p < 0.01 and p < 0.05, respectively). For the metastasis model, R-C12 or R-C12-4 was applied by the tail intravenous injection every 2 days at the dose of 10 mg/kg. As shown in Figure 7D, significantly fewer metastatic nodules from the lungs of Kunming (KM) mice were observed in the R-C12-4 and R-C12 treatment groups compared to the control and this result was confirmed by the H&E staining of lung sections. Visible tumor nodules were counted on the surface of the lung demonstrating a significant difference between the control and R-C12 and R-C12-4 treatment groups (p < 0.05). It is noteworthy that both R-C12 and R-C12-4 did not affect the mouse body weight either in the subcutaneous transplantation model or in the metastasis model, indicating that these peptides did not diminish their overall health.

   Click to Show/Hide
In Vivo Model KM mice B16-F10 cells xenograft model.
In Vitro Model Mouse melanoma B16-F10 cell CVCL_0159
Experiment 3 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Tumor growth inhibition value (TGI)
62.50%
Administration Time 9 days
Administration Dosage 200 μL 15 mg/kg
MOA of PDC
In this study, we would investigate the co-modification of fatty acids and monosaccharides in anticancer peptides, as we expect to optimize the selectivity and cytotoxicity of the peptide at the same time. Based on our previous study, the lipopeptide R-C12 was selected as a template to perform glucose derivative modification at different positions as we supposed that the glucose derivative modification position in R-C12 might be a crucial factor in its selectivity and activity optimization. The glucose derivative was covalently coupled to different sites in R-C12 through its -amino group of a Lys residue, which was obtained by replacing the Arg residue. R-C12 contains seven Arg residues, accordingly, seven glycolipid peptides were designed and synthesized, which were named R-C12-1, R-C12-2, R-C12-3, R-C12-4, R-C12-5, R-C12-6, and R-C12-7. Various physiochemical properties including the hydrodynamic size, ζ-potential, secondary structure, and hydrophobicity were determined to explain the different cytotoxicity and selectivity of these glycolipid peptides. On the other hand, the strength of the binding between glycolipid peptides and the cancer cells mediated by GLUT1 has also been explored. The most optimized glycolipid peptide R-C12-4 demonstrated significant cytotoxicity and antimetastasis in vitro and in vivo, which indicated that it may be a good lead for anticancer drug development.

   Click to Show/Hide
Description
For the subcutaneous transplantation model, R-C12 or R-C12-4 was injected intraperitoneally every other day at the dose of 15 mg/kg. As shown in Figure 7A,B, after 12 days, R-C12-4 and R-C12 have a significant inhibition effect on the BALB/c mice tumor volume compared to the control group (p < 0.01 and p < 0.05, respectively). For the metastasis model, R-C12 or R-C12-4 was applied by the tail intravenous injection every 2 days at the dose of 10 mg/kg. As shown in Figure 7D, significantly fewer metastatic nodules from the lungs of Kunming (KM) mice were observed in the R-C12-4 and R-C12 treatment groups compared to the control and this result was confirmed by the H&E staining of lung sections. Visible tumor nodules were counted on the surface of the lung demonstrating a significant difference between the control and R-C12 and R-C12-4 treatment groups (p < 0.05). It is noteworthy that both R-C12 and R-C12-4 did not affect the mouse body weight either in the subcutaneous transplantation model or in the metastasis model, indicating that these peptides did not diminish their overall health.

   Click to Show/Hide
In Vivo Model KM mice B16-F10 cells xenograft model.
In Vitro Model Mouse melanoma B16-F10 cell CVCL_0159
Experiment 4 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Tumor growth inhibition value (TGI)
73.70%
Administration Time 12 days
Administration Dosage 200 μL 15 mg/kg
MOA of PDC
In this study, we would investigate the co-modification of fatty acids and monosaccharides in anticancer peptides, as we expect to optimize the selectivity and cytotoxicity of the peptide at the same time. Based on our previous study, the lipopeptide R-C12 was selected as a template to perform glucose derivative modification at different positions as we supposed that the glucose derivative modification position in R-C12 might be a crucial factor in its selectivity and activity optimization. The glucose derivative was covalently coupled to different sites in R-C12 through its -amino group of a Lys residue, which was obtained by replacing the Arg residue. R-C12 contains seven Arg residues, accordingly, seven glycolipid peptides were designed and synthesized, which were named R-C12-1, R-C12-2, R-C12-3, R-C12-4, R-C12-5, R-C12-6, and R-C12-7. Various physiochemical properties including the hydrodynamic size, ζ-potential, secondary structure, and hydrophobicity were determined to explain the different cytotoxicity and selectivity of these glycolipid peptides. On the other hand, the strength of the binding between glycolipid peptides and the cancer cells mediated by GLUT1 has also been explored. The most optimized glycolipid peptide R-C12-4 demonstrated significant cytotoxicity and antimetastasis in vitro and in vivo, which indicated that it may be a good lead for anticancer drug development.

   Click to Show/Hide
Description
For the subcutaneous transplantation model, R-C12 or R-C12-4 was injected intraperitoneally every other day at the dose of 15 mg/kg. As shown in Figure 7A,B, after 12 days, R-C12-4 and R-C12 have a significant inhibition effect on the BALB/c mice tumor volume compared to the control group (p < 0.01 and p < 0.05, respectively). For the metastasis model, R-C12 or R-C12-4 was applied by the tail intravenous injection every 2 days at the dose of 10 mg/kg. As shown in Figure 7D, significantly fewer metastatic nodules from the lungs of Kunming (KM) mice were observed in the R-C12-4 and R-C12 treatment groups compared to the control and this result was confirmed by the H&E staining of lung sections. Visible tumor nodules were counted on the surface of the lung demonstrating a significant difference between the control and R-C12 and R-C12-4 treatment groups (p < 0.05). It is noteworthy that both R-C12 and R-C12-4 did not affect the mouse body weight either in the subcutaneous transplantation model or in the metastasis model, indicating that these peptides did not diminish their overall health.

   Click to Show/Hide
In Vivo Model KM mice B16-F10 cells xenograft model.
In Vitro Model Mouse melanoma B16-F10 cell CVCL_0159
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Half maximal inhibitory concentration (IC50)
1.9 μM
Administration Time 24 h
Evaluation Method CCK-8 assay
MOA of PDC
In this study, we would investigate the co-modification of fatty acids and monosaccharides in anticancer peptides, as we expect to optimize the selectivity and cytotoxicity of the peptide at the same time. Based on our previous study, the lipopeptide R-C12 was selected as a template to perform glucose derivative modification at different positions as we supposed that the glucose derivative modification position in R-C12 might be a crucial factor in its selectivity and activity optimization. The glucose derivative was covalently coupled to different sites in R-C12 through its -amino group of a Lys residue, which was obtained by replacing the Arg residue. R-C12 contains seven Arg residues, accordingly, seven glycolipid peptides were designed and synthesized, which were named R-C12-1, R-C12-2, R-C12-3, R-C12-4, R-C12-5, R-C12-6, and R-C12-7. Various physiochemical properties including the hydrodynamic size, ζ-potential, secondary structure, and hydrophobicity were determined to explain the different cytotoxicity and selectivity of these glycolipid peptides. On the other hand, the strength of the binding between glycolipid peptides and the cancer cells mediated by GLUT1 has also been explored. The most optimized glycolipid peptide R-C12-4 demonstrated significant cytotoxicity and antimetastasis in vitro and in vivo, which indicated that it may be a good lead for anticancer drug development.

   Click to Show/Hide
Description
Murine melanoma cells (B16-F10) were chosen as the object for evaluating the cytotoxicity of the seven glycolipid peptides and R-C12 by the CCK-8 assay. Based on our previous study, the HEK-293T cell line was also chosen as the noncancer cell line to evaluate the selectivity of glycolipid peptides. IC50 represents the concentration of glycolipid peptides and R-C12 that induce 50% cell death. As shown in Figure 1A, modification of the glucose derivative at different sites of R-C12 results in different cytotoxicity profiles. According to the IC50 values, for B16-F10 cells, the cytotoxic activity of peptides was arranged as follows R-C12-4 > R-C12-1 ≈ R-C12-2 ≈ R-C12-3 ≈ R-C12 > R-C12-5 > R-C12-6 > R-C12-7, in which R-C12-4 demonstrated the highest cytotoxicity on B16-F10 cells (IC50 = 1.9 μM)

   Click to Show/Hide
In Vitro Model Mouse melanoma B16-F10 cell CVCL_0159
R-C12-2 [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Half maximal inhibitory concentration (IC50)
3.3 μM
Administration Time 24 h
Evaluation Method CCK-8 assay
MOA of PDC
In this study, we would investigate the co-modification of fatty acids and monosaccharides in anticancer peptides, as we expect to optimize the selectivity and cytotoxicity of the peptide at the same time. Based on our previous study, the lipopeptide R-C12 was selected as a template to perform glucose derivative modification at different positions as we supposed that the glucose derivative modification position in R-C12 might be a crucial factor in its selectivity and activity optimization. The glucose derivative was covalently coupled to different sites in R-C12 through its -amino group of a Lys residue, which was obtained by replacing the Arg residue. R-C12 contains seven Arg residues, accordingly, seven glycolipid peptides were designed and synthesized, which were named R-C12-1, R-C12-2, R-C12-3, R-C12-4, R-C12-5, R-C12-6, and R-C12-7. Various physiochemical properties including the hydrodynamic size, ζ-potential, secondary structure, and hydrophobicity were determined to explain the different cytotoxicity and selectivity of these glycolipid peptides. On the other hand, the strength of the binding between glycolipid peptides and the cancer cells mediated by GLUT1 has also been explored. The most optimized glycolipid peptide R-C12-4 demonstrated significant cytotoxicity and antimetastasis in vitro and in vivo, which indicated that it may be a good lead for anticancer drug development.

   Click to Show/Hide
Description
Murine melanoma cells (B16-F10) were chosen as the object for evaluating the cytotoxicity of the seven glycolipid peptides and R-C12 by the CCK-8 assay. Based on our previous study, the HEK-293T cell line was also chosen as the noncancer cell line to evaluate the selectivity of glycolipid peptides. IC50 represents the concentration of glycolipid peptides and R-C12 that induce 50% cell death. As shown in Figure 1A, modification of the glucose derivative at different sites of R-C12 results in different cytotoxicity profiles. According to the IC50 values, for B16-F10 cells, the cytotoxic activity of peptides was arranged as follows R-C12-4 > R-C12-1 ≈ R-C12-2 ≈ R-C12-3 ≈ R-C12 > R-C12-5 > R-C12-6 > R-C12-7, in which R-C12-4 demonstrated the highest cytotoxicity on B16-F10 cells (IC50 = 1.9 μM)

   Click to Show/Hide
In Vitro Model Mouse melanoma B16-F10 cell CVCL_0159
R-C12-1 [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Half maximal inhibitory concentration (IC50)
3.5 μM
Administration Time 24 h
Evaluation Method CCK-8 assay
MOA of PDC
In this study, we would investigate the co-modification of fatty acids and monosaccharides in anticancer peptides, as we expect to optimize the selectivity and cytotoxicity of the peptide at the same time. Based on our previous study, the lipopeptide R-C12 was selected as a template to perform glucose derivative modification at different positions as we supposed that the glucose derivative modification position in R-C12 might be a crucial factor in its selectivity and activity optimization. The glucose derivative was covalently coupled to different sites in R-C12 through its -amino group of a Lys residue, which was obtained by replacing the Arg residue. R-C12 contains seven Arg residues, accordingly, seven glycolipid peptides were designed and synthesized, which were named R-C12-1, R-C12-2, R-C12-3, R-C12-4, R-C12-5, R-C12-6, and R-C12-7. Various physiochemical properties including the hydrodynamic size, ζ-potential, secondary structure, and hydrophobicity were determined to explain the different cytotoxicity and selectivity of these glycolipid peptides. On the other hand, the strength of the binding between glycolipid peptides and the cancer cells mediated by GLUT1 has also been explored. The most optimized glycolipid peptide R-C12-4 demonstrated significant cytotoxicity and antimetastasis in vitro and in vivo, which indicated that it may be a good lead for anticancer drug development.

   Click to Show/Hide
Description
Murine melanoma cells (B16-F10) were chosen as the object for evaluating the cytotoxicity of the seven glycolipid peptides and R-C12 by the CCK-8 assay. Based on our previous study, the HEK-293T cell line was also chosen as the noncancer cell line to evaluate the selectivity of glycolipid peptides. IC50 represents the concentration of glycolipid peptides and R-C12 that induce 50% cell death. As shown in Figure 1A, modification of the glucose derivative at different sites of R-C12 results in different cytotoxicity profiles. According to the IC50 values, for B16-F10 cells, the cytotoxic activity of peptides was arranged as follows R-C12-4 > R-C12-1 ≈ R-C12-2 ≈ R-C12-3 ≈ R-C12 > R-C12-5 > R-C12-6 > R-C12-7, in which R-C12-4 demonstrated the highest cytotoxicity on B16-F10 cells (IC50 = 1.9 μM)

   Click to Show/Hide
In Vitro Model Mouse melanoma B16-F10 cell CVCL_0159
R-C12-3 [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Half maximal inhibitory concentration (IC50)
3.8 μM
Administration Time 24 h
Evaluation Method CCK-8 assay
MOA of PDC
In this study, we would investigate the co-modification of fatty acids and monosaccharides in anticancer peptides, as we expect to optimize the selectivity and cytotoxicity of the peptide at the same time. Based on our previous study, the lipopeptide R-C12 was selected as a template to perform glucose derivative modification at different positions as we supposed that the glucose derivative modification position in R-C12 might be a crucial factor in its selectivity and activity optimization. The glucose derivative was covalently coupled to different sites in R-C12 through its -amino group of a Lys residue, which was obtained by replacing the Arg residue. R-C12 contains seven Arg residues, accordingly, seven glycolipid peptides were designed and synthesized, which were named R-C12-1, R-C12-2, R-C12-3, R-C12-4, R-C12-5, R-C12-6, and R-C12-7. Various physiochemical properties including the hydrodynamic size, ζ-potential, secondary structure, and hydrophobicity were determined to explain the different cytotoxicity and selectivity of these glycolipid peptides. On the other hand, the strength of the binding between glycolipid peptides and the cancer cells mediated by GLUT1 has also been explored. The most optimized glycolipid peptide R-C12-4 demonstrated significant cytotoxicity and antimetastasis in vitro and in vivo, which indicated that it may be a good lead for anticancer drug development.

   Click to Show/Hide
Description
Murine melanoma cells (B16-F10) were chosen as the object for evaluating the cytotoxicity of the seven glycolipid peptides and R-C12 by the CCK-8 assay. Based on our previous study, the HEK-293T cell line was also chosen as the noncancer cell line to evaluate the selectivity of glycolipid peptides. IC50 represents the concentration of glycolipid peptides and R-C12 that induce 50% cell death. As shown in Figure 1A, modification of the glucose derivative at different sites of R-C12 results in different cytotoxicity profiles. According to the IC50 values, for B16-F10 cells, the cytotoxic activity of peptides was arranged as follows R-C12-4 > R-C12-1 ≈ R-C12-2 ≈ R-C12-3 ≈ R-C12 > R-C12-5 > R-C12-6 > R-C12-7, in which R-C12-4 demonstrated the highest cytotoxicity on B16-F10 cells (IC50 = 1.9 μM)

   Click to Show/Hide
In Vitro Model Mouse melanoma B16-F10 cell CVCL_0159
R-C12-5 [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Half maximal inhibitory concentration (IC50)
4.1 μM
Administration Time 24 h
Evaluation Method CCK-8 assay
MOA of PDC
In this study, we would investigate the co-modification of fatty acids and monosaccharides in anticancer peptides, as we expect to optimize the selectivity and cytotoxicity of the peptide at the same time. Based on our previous study, the lipopeptide R-C12 was selected as a template to perform glucose derivative modification at different positions as we supposed that the glucose derivative modification position in R-C12 might be a crucial factor in its selectivity and activity optimization. The glucose derivative was covalently coupled to different sites in R-C12 through its -amino group of a Lys residue, which was obtained by replacing the Arg residue. R-C12 contains seven Arg residues, accordingly, seven glycolipid peptides were designed and synthesized, which were named R-C12-1, R-C12-2, R-C12-3, R-C12-4, R-C12-5, R-C12-6, and R-C12-7. Various physiochemical properties including the hydrodynamic size, ζ-potential, secondary structure, and hydrophobicity were determined to explain the different cytotoxicity and selectivity of these glycolipid peptides. On the other hand, the strength of the binding between glycolipid peptides and the cancer cells mediated by GLUT1 has also been explored. The most optimized glycolipid peptide R-C12-4 demonstrated significant cytotoxicity and antimetastasis in vitro and in vivo, which indicated that it may be a good lead for anticancer drug development.

   Click to Show/Hide
Description
Murine melanoma cells (B16-F10) were chosen as the object for evaluating the cytotoxicity of the seven glycolipid peptides and R-C12 by the CCK-8 assay. Based on our previous study, the HEK-293T cell line was also chosen as the noncancer cell line to evaluate the selectivity of glycolipid peptides. IC50 represents the concentration of glycolipid peptides and R-C12 that induce 50% cell death. As shown in Figure 1A, modification of the glucose derivative at different sites of R-C12 results in different cytotoxicity profiles. According to the IC50 values, for B16-F10 cells, the cytotoxic activity of peptides was arranged as follows R-C12-4 > R-C12-1 ≈ R-C12-2 ≈ R-C12-3 ≈ R-C12 > R-C12-5 > R-C12-6 > R-C12-7, in which R-C12-4 demonstrated the highest cytotoxicity on B16-F10 cells (IC50 = 1.9 μM)

   Click to Show/Hide
In Vitro Model Mouse melanoma B16-F10 cell CVCL_0159
R-C12-6 [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Half maximal inhibitory concentration (IC50)
5.3 μM
Administration Time 24 h
Evaluation Method CCK-8 assay
MOA of PDC
In this study, we would investigate the co-modification of fatty acids and monosaccharides in anticancer peptides, as we expect to optimize the selectivity and cytotoxicity of the peptide at the same time. Based on our previous study, the lipopeptide R-C12 was selected as a template to perform glucose derivative modification at different positions as we supposed that the glucose derivative modification position in R-C12 might be a crucial factor in its selectivity and activity optimization. The glucose derivative was covalently coupled to different sites in R-C12 through its -amino group of a Lys residue, which was obtained by replacing the Arg residue. R-C12 contains seven Arg residues, accordingly, seven glycolipid peptides were designed and synthesized, which were named R-C12-1, R-C12-2, R-C12-3, R-C12-4, R-C12-5, R-C12-6, and R-C12-7. Various physiochemical properties including the hydrodynamic size, ζ-potential, secondary structure, and hydrophobicity were determined to explain the different cytotoxicity and selectivity of these glycolipid peptides. On the other hand, the strength of the binding between glycolipid peptides and the cancer cells mediated by GLUT1 has also been explored. The most optimized glycolipid peptide R-C12-4 demonstrated significant cytotoxicity and antimetastasis in vitro and in vivo, which indicated that it may be a good lead for anticancer drug development.

   Click to Show/Hide
Description
Murine melanoma cells (B16-F10) were chosen as the object for evaluating the cytotoxicity of the seven glycolipid peptides and R-C12 by the CCK-8 assay. Based on our previous study, the HEK-293T cell line was also chosen as the noncancer cell line to evaluate the selectivity of glycolipid peptides. IC50 represents the concentration of glycolipid peptides and R-C12 that induce 50% cell death. As shown in Figure 1A, modification of the glucose derivative at different sites of R-C12 results in different cytotoxicity profiles. According to the IC50 values, for B16-F10 cells, the cytotoxic activity of peptides was arranged as follows R-C12-4 > R-C12-1 ≈ R-C12-2 ≈ R-C12-3 ≈ R-C12 > R-C12-5 > R-C12-6 > R-C12-7, in which R-C12-4 demonstrated the highest cytotoxicity on B16-F10 cells (IC50 = 1.9 μM)

   Click to Show/Hide
In Vitro Model Mouse melanoma B16-F10 cell CVCL_0159
R-C12-7 [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Half maximal inhibitory concentration (IC50)
7.2 μM
Administration Time 24 h
Evaluation Method CCK-8 assay
MOA of PDC
In this study, we would investigate the co-modification of fatty acids and monosaccharides in anticancer peptides, as we expect to optimize the selectivity and cytotoxicity of the peptide at the same time. Based on our previous study, the lipopeptide R-C12 was selected as a template to perform glucose derivative modification at different positions as we supposed that the glucose derivative modification position in R-C12 might be a crucial factor in its selectivity and activity optimization. The glucose derivative was covalently coupled to different sites in R-C12 through its -amino group of a Lys residue, which was obtained by replacing the Arg residue. R-C12 contains seven Arg residues, accordingly, seven glycolipid peptides were designed and synthesized, which were named R-C12-1, R-C12-2, R-C12-3, R-C12-4, R-C12-5, R-C12-6, and R-C12-7. Various physiochemical properties including the hydrodynamic size, ζ-potential, secondary structure, and hydrophobicity were determined to explain the different cytotoxicity and selectivity of these glycolipid peptides. On the other hand, the strength of the binding between glycolipid peptides and the cancer cells mediated by GLUT1 has also been explored. The most optimized glycolipid peptide R-C12-4 demonstrated significant cytotoxicity and antimetastasis in vitro and in vivo, which indicated that it may be a good lead for anticancer drug development.

   Click to Show/Hide
Description
Murine melanoma cells (B16-F10) were chosen as the object for evaluating the cytotoxicity of the seven glycolipid peptides and R-C12 by the CCK-8 assay. Based on our previous study, the HEK-293T cell line was also chosen as the noncancer cell line to evaluate the selectivity of glycolipid peptides. IC50 represents the concentration of glycolipid peptides and R-C12 that induce 50% cell death. As shown in Figure 1A, modification of the glucose derivative at different sites of R-C12 results in different cytotoxicity profiles. According to the IC50 values, for B16-F10 cells, the cytotoxic activity of peptides was arranged as follows R-C12-4 > R-C12-1 ≈ R-C12-2 ≈ R-C12-3 ≈ R-C12 > R-C12-5 > R-C12-6 > R-C12-7, in which R-C12-4 demonstrated the highest cytotoxicity on B16-F10 cells (IC50 = 1.9 μM)

   Click to Show/Hide
In Vitro Model Mouse melanoma B16-F10 cell CVCL_0159
References
Ref 1 Glucose-Lipopeptide Conjugates Reveal the Role of Glucose Modification Position in Complexation and the Potential of Malignant Melanoma Therapy. J Med Chem. 2021 Aug 12;64(15):11483-11495. doi: 10.1021/acs.jmedchem.1c00805. Epub 2021 Jul 20.